Sunitinib Malate (formerly also known as SU11248 Malate; trade nameSutent)) is a potent, orally bioavailable and multi-targeted RTK (receptor tyrosine kinase) inhibitor with potent anticancer activities.

Vatalanib (PTK787 or ZK-222584, cpg-79787 2HCl) 2HCl is a novel, potent and orally bioavailable inhibitor of VEGFR2/KDR with potential anticancer activity.

Foretinib (also known as GSK1363089; XL880; EXEL-2880; GSK089) is a novel, potent, ATP-competitive small-molecule inhibitor of multiple tyrosine kinases (e.g. VEGF) with potential antineoplastic activity.

LY2874455 (LY-2874455; LY 2874455) is a novel and highly potent pan-FGFR inhibitor with potential anticancer activity.

BIBF-1202 (BIBF1202; BIBF 1202) is the carboxylate metabolite of Nintedanib (formerly BIBF-1120; Vargatef), which is an approved anticancer medication acting as an orally bioavailable triple angiokinase (VEGFR, PDGFR, FGFR) inhibitor.

Tivozanib (formerly KRN951 or AV-951; brand name Fotivda) is a novel, orally bioavailable, potent and selective inhibitor of VEGFR (vascular endothelial growth factor receptors) with potential antineoplastic activity.

Dovitinib (formerly also known as TKI-258 or CHIR-258) is a potent, orally bioavailable and multi-targeted RTK (receptor tyrosine kinase) inhibitor with potential antineoplastic activity.

ENMD-2076 Tartrate, the tartrate salt of ENMD-981693 (MKC-1693), is a novel, potent and orally bioactive multi-kinase inhibitor with potential antineoplastic activity.

SU5614 is a potent and selective FLT3 inhibitor.

Cediranib (also called NSC732208; AZD2171, tentative trade name Recenti), an indole ether quinazoline derivative, is a potent and oral VEGFR (vascular endothelial growth factor receptors) inhibitor with potential antitumor activity.